Diversity in clinical trials is essential for developing generalisable treatments, but in a recent survey, only 26% of CNS drug developers reported using diversity plans. Learn best practices for conducting inclusive neurodegenerative trials in our whitepaper. Download the whitepaper: https://ow.ly/tTbX50UU6ip
